Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review

Date: August 2, 2016
Pages: 69
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: VE656B9CD2CEN
Leaflet:

Download PDF Leaflet

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Valeant Pharmaceuticals International, Inc. (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International, Inc. Key Recent Developments

Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
Jun 27, 2016: Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
Jun 16, 2016: Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Valeant Pharmaceuticals International, Inc. - Key Facts
Valeant Pharmaceuticals International, Inc. - Key Employees
Valeant Pharmaceuticals International, Inc. - Key Employee Biographies
Valeant Pharmaceuticals International, Inc. - Major Products and Services
Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc. - History
Valeant Pharmaceuticals International, Inc. - Company Statement
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Valeant Pharmaceuticals International, Inc. - Business Description
Valeant Pharmaceuticals International, Inc. - Corporate Strategy
Valeant Pharmaceuticals International, Inc. - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International, Inc. - Strengths
Strength - Core Segment: Pharmaceuticals
Strength - Focus on Research & Development Activities
Strength - Business Partnerships
Valeant Pharmaceuticals International, Inc. - Weaknesses
Weakness - Patent Infringement Concerns
Weakness - Virazole - Microbial Contamination
Weakness - Higher Cost Structure
Valeant Pharmaceuticals International, Inc. - Opportunities
Opportunity - Global Dermatology Market
Opportunity - Product Pipeline
Opportunity - Inorganic Growth: Strategic Acquisitions
Valeant Pharmaceuticals International, Inc. - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Reliance on Major Customers
Valeant Pharmaceuticals International, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Valeant Pharmaceuticals International, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
Jun 16, 2016: Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller
May 16, 2016: Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel
May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters
May 16, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters
May 05, 2016: Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Valeant Pharmaceuticals International, Inc., Key Facts
Valeant Pharmaceuticals International, Inc., Key Employees
Valeant Pharmaceuticals International, Inc., Key Employee Biographies
Valeant Pharmaceuticals International, Inc., Major Products and Services
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage
Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase
Valeant Pharmaceuticals International, Inc., History
Valeant Pharmaceuticals International, Inc., Other Locations
Valeant Pharmaceuticals International, Inc., Subsidiaries
Valeant Pharmaceuticals International, Inc., Key Competitors
Valeant Pharmaceuticals International, Inc., Ratios based on current share price
Valeant Pharmaceuticals International, Inc., Annual Ratios
Valeant Pharmaceuticals International, Inc., Interim Ratios
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc., Performance Chart (2011 - 2015)
Valeant Pharmaceuticals International, Inc., Ratio Charts
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Xenon Pharmaceuticals Inc.
Stratus Pharmaceuticals, Inc.
Sirona Biochem Corp
Polydex Pharmaceuticals Limited
Pfizer Canada Inc.
Opiant Pharmaceuticals, Inc.
Mylan N.V.
Maruho Co., Ltd.
GTx, Inc.
Endo International Plc
AIM Therapeutics Inc.
Skip to top


Ask Your Question

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: